PMCF Study on the Safety and Performance of the Zimmer® Maxera™ Acetabular System in Total Hip Arthroplasty
← catalyst calendarNCT03372278 · readout ≤ 165 d
Sponsored by Zimmer Biomet (industry) · ZBH — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
250actual
Sites
8
Countries
Australia, Belgium, Canada +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Jan 2013 | actual | When the study began enrolling |
| Primary completion | Jan 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2017-12-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Rheumatoid Arthritis With Adequate Bone Quality
- Inflammatory Arthritis
- Osteoarthritis, Hip
- Avascular Necrosis
- Post-traumatic; Arthrosis
- Congenital Hip Dysplasia
Primary outcome
what the primary-completion date above is the date OFImplant survival based on removal or intended removal of the device and determined using the Kaplan-Meier method
measured 10 years post-surgery
Permalink · ZBH's whole pipeline · Catalyst calendar · Every registered study · What changed